Poor accrual

This phase II trial is studying how well temsirolimus works in treating patients with recurrent or persistent cancer of the uterus. Temsirolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

PRIMARY OBJECTIVES:

I. Assess the efficacy of Temsirolimus in women with recurrent or persistent (after primary therapy) Carcinosarcoma (MMMT) of the uterus.

II. Assess the safety and tolerability of Temsirolimus in this patient population.

III. Evaluate secondary efficacy endpoints of time to tumor progression, progression-free survival (PFS), 6 month PFS rate, and duration of response.

SECONDARY OBJECTIVES:

I. Overall survival II.Duration of Response III. Time to progression IV. Time to treatment failure

OUTLINE: This is a multicenter study.

Patients receive temsirolimus IV over 30 minutes on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.

After completion of study therapy, patients are followed up periodically for up to 3 years.

Inclusion Criteria:

• Histologically or cytologically confirmed Carcinosarcoma (MMMT)

• Measurable disease;

• Only one prior systemic treatments after primary adjuvant treatment for persistent or metastatic disease are permitted,

• Radiation therapy (adjuvant or palliative) must be completed ≥ 4 weeks prior to registration

• Required laboratory values obtained =< 7 days prior to registration:

• Absolute Neutrophil Count (ANC) >= 1500/mm^3

• Platelets >= 75,000/mm^3

• Hemoglobin >= 9.0 g/dL

• Direct bilirubin =< 1.5 x upper limit of normal (ULN)

• Alkaline phosphatase =< 2.5 x ULN (≤ 5 x ULN if liver metastasis is present)

• SGOT(AST) =< 2.5 x ULN (≤ 5 x ULN if liver metastasis is present)

• Creatinine =< 1.5 x ULN

• Fasting serum cholesterol ≤ 350mg/dL (9.0 mmol/L)

• Triglycerides ≤ 1.5 x ULN

  • Patients with Triglyceride levels > 1.5 x ULN can be started on lipid lowering agents and reevaluated within 1 week; if levels go to ≤ 1.5 x ULN, they can be considered for the trial and continue the lipid lowering agents

• International Normalized Ratio (INR) ≤ 1.5 (unless the patient is on full dose warfarin)

• ECOG Performance Status (PS) 0-1

• Capable of understanding the investigational nature, potential risks and benefits of the study and able to provide valid informed consent

• Full-dose anticoagulants, if a patient is receiving full-dose anticoagulants, the following criteria should be met for enrollment:

  • The subject must have an in-range INR (usually between 2 and 3) on a stable dose of warfarin or on stable dose of LMW heparin

• Patients who have had prior anthracycline must have a normal ejection fraction on LVEF assessment by MUGA or Echo ≤ 4 weeks prior to registration

• Availability of tissue samples or blocks (from the primary tumor or metastases) for tumor studies

• Willingness to donate blood for correlative marker studies

Exclusion Criteria:

• Prior therapy with Temsirolimus or another mTOR inhibitors

• Patients cannot be receiving enzyme-inducing antiepileptic drugs (EIAEDs; e.g., phenytoin, carbamazepine, phenobarbital) nor any other CYP3A4 inducer such as rifampin or St. John's wort

• Untreated central nervous system (CNS) metastases; exceptions: patients with known CNS metastases can be enrolled if the brain metastases have been adequately treated and there is no evidence of progression or hemorrhage after treatment as ascertained by clinical examination and brain imaging (MRI or CT) ≤ 12 weeks prior to registration and no ongoing requirement for steroids

  • Anticonvulsants (stable dose) are allowed
  • Patients who had surgical resection of CNS metastases or brain biopsy ≤ 3 months prior to registration will be excluded

• Pregnant or lactating wome

• Currently active, second malignancy other than non-melanoma skin cancers; - Other uncontrolled serious medical or psychiatric condition (e.g. cardiac arrhythmias, diabetes, etc.)

• Active infection requiring antibiotics

• Received prior radiotherapy to any portion of the abdominal cavity or pelvis OTHER THAN for the treatment of endometrial cancer

• Radiation therapy to > 50% of marrow bearing areas